Cytosorbents (NASDAQ:CTSO) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Cytosorbents (NASDAQ:CTSO) posted its quarterly earnings data on Tuesday. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01, Zacks reports. The business had revenue of $9.89 million during the quarter, compared to the consensus estimate of $9.73 million. Cytosorbents had a negative net margin of 75.07% and a negative return on equity of 129.89%. During the same period in the prior year, the firm earned ($0.14) EPS.

Cytosorbents Stock Performance

Cytosorbents stock traded up $0.02 during mid-day trading on Wednesday, reaching $0.92. The company had a trading volume of 10,577 shares, compared to its average volume of 132,296. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $2.95. The firm has a market cap of $49.91 million, a price-to-earnings ratio of -1.52 and a beta of 0.57. The company has a quick ratio of 1.21, a current ratio of 1.49 and a debt-to-equity ratio of 0.10. The company has a 50 day moving average of $0.95 and a 200-day moving average of $0.94.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on CTSO shares. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a report on Wednesday. StockNews.com assumed coverage on shares of Cytosorbents in a report on Wednesday. They issued a “hold” rating for the company. B. Riley reissued a “buy” rating and issued a $3.00 price target on shares of Cytosorbents in a report on Wednesday, May 15th. Finally, EF Hutton Acquisition Co. I raised shares of Cytosorbents to a “strong-buy” rating in a report on Monday, July 29th.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.